Navigation Links
Resverlogix Activates First Site for ASSURE 1 Clinical Trial
Date:2/25/2010

na spent her time in the laboratory as a biologist with Genentech and the University of Utah.

Tina has fifteen years of combined experience working in diverse corporate cultures from start-ups to multinationals. In the last 10 years she has worked in Global Project Management where she was primarily accountable for team leadership, strategic planning and financial management. Some of her key strengths are leading cross-functional internal and partnered global development teams in accomplishing business driven milestones on time and within budget. Tina received her B.S. from the University of Utah and her MBA from Duke University

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT). RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Resverlogix Completes Patient Recruitment for ASSERT Trial
2. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
3. Resverlogix Presenting at Biotech Showcase
4. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
5. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
6. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
7. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
8. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
9. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
10. Resverlogix Provides Quarterly Update
11. Resverlogix Board of Directors Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... VetStem ... a live stem cell credentialing course to local area veterinarians. , The tour and ... approved CE units at no charge) at VetStem’s Poway facility. Staff members are welcome ...
(Date:7/28/2015)... 28, 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) ... company, today announced that its stockholders approved an increase ... of the Company from 1,000,000,000 to 2,500,000,000 at its ... at the Law Offices of Nixon Peabody LLP in ... there were 480,655,929 shares of common stock represented either ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix ... Phase 1 clinical trial with MMI-0100, a first-in-class ... being developed for pulmonary disorders characterized by inflammation ... United Kingdom , is a double-blind, ... evaluating the safety and tolerability of MMI-0100 when ...
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
... N.C., June 27, 2011 Chimerix, Inc., ... an agreement with the Biomedical Advanced Research and Development ... and Human Services (HHS) that will resolve the Government ... contract awarded to SIGA Technologies, Inc. for the development ...
... With a 150 year expertise in the genetic improvement ... globally focused outlook, New Zealand,s biotech industry is well ... products. Led by industry organization NZBIO and New Zealand ... are showcasing their capabilities in human health care, animal ...
... a subsidiary of Eisai Inc., announced today that it has ... from its employees, more than 5 times as much as ... this number equates to over 40 pounds of food donated ... families through collaboration with Philabundance, the area,s largest food bank ...
Cached Biology Technology:Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract 2Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract 3Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract 4New Zealand Brings Its Global "Game Plan" to the 2011 BIO International Convention 2Morphotek, Inc. Employees Collect Nearly 9,000 Pounds of Food for Local Families 2Morphotek, Inc. Employees Collect Nearly 9,000 Pounds of Food for Local Families 3
(Date:6/26/2015)... Utah , June 26, 2015 ATL Technology, ... and devices with specialties in single use solutions, headquartered in ... of MedConx, Inc. (a California corporation ... and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility ...
(Date:6/25/2015)... June 25, 2015  TAKE Solutions Ltd., a global ... the United States Patent and Trademark Office (USPTO) for ... leverages TAKE Solutions, Clinical Accelerators to reduce the time ... compared to standardization without the accelerators), thus reducing time ... At the heart of the patented Clinical ...
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... well-known fact in drug trials that individuals can respond just ... drug. On the other hand, it is difficult to ... A team of researchers from Uppsala University and Gothenburg University ... effect and a mechanism in the brain that characterizes those ...
... IL, December 3, 2008 Today, the International Society ... organization of stem cell researchers, released new guidelines for ... therapies for patients. A Commentary article that summarizes the ... be published by Cell Press in the December issue ...
... Synthetic biology promises to enable cheap, lifesaving new drugs ... malaria, and to create innovative biofuels that can help ... and its applications are raising questions: Are synthetic ... the definition of what is life? Are synthetic ...
Cached Biology News:Genes determine whether sugar pills work 2The International Society for Stem Cell Research releases new guidelines 2The International Society for Stem Cell Research releases new guidelines 3Synthetic biology: Is ethics a showstopper? 2